Bruker Introduces maXis HD Ultra-High Resolution QTOF
At the 12th Human Proteome Organization World Congress (www.hupo.org/2013), Bruker completed its series of High-Definition (HD) QTOF systems introductions with the launch of its new flagship maXis HD ultra-high resolution (UHR) QTOF mass spectrometer. With its best-in-class full sensitivity resolution (FSR) greater than 75,000, the new maXis HD is ideally suited for top-down proteomic analyses and the characterisation of biopharmaceuticals.
The novel maXis HD features a new High-Definition Collision (HDC) cell which enables its record-breaking full sensitivity mass resolution, as well as accurate mass capabilities well beyond all competing QTOF As a result of its extreme sensitivity broad mass-transfer ion optics and the fastest available 50 Gbit/s sampling technology, a dynamic range of five orders of magnitude is achieved in one second of LC time. High dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct identification and quantitation without re-runs.
The maXis HD offers break-through analytical performance for applications in top-down proteomics and in biopharmaceutical compound analysis, and the instrument excels in the analysis of intact proteins and antibodies. For antibody subunits, it can provide unprecedented insight into antibody structures via its ultra-high resolution at high mass with baseline discrimination of isotope envelopes at excellent mass accuracy.
The maXis HD also delivers a new confidence level in the fast, high-resolution, accurate mass screening, identification and quantification of small molecules. The novel HDC cell and HD detection technology translate directly into enhanced dynamic range and extreme sensitivity down to very low masses at UHPLC speed, a precondition for one-shot plug and play acquisitions in multi-target applications. The recording-breaking full sensitivity resolution in combination with the Bruker proprietary, real-time SmartFormula 3D software makes the maXis HD the tool of choice for true unknown screening and the ab initio determination of elemental composition at UHPLC speed and throughput.
Dr Michael Schubert, President of the Bruker Daltonics Life-Science & Clinical Division, stated: “With these performance features we believe that the new maXis HD delivers the fastest time-to-success for customers across a broad applications portfolio, covering small molecule identification and characterisation; food, forensic and environmental screening; metabolomics; as well as top-down proteomics and antibody analysis."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance